Our doors opened 21 years ago in 1995 as one of the first bio-business incubators in the nation. Sixty-one companies, $1.53 billion dollars of client funding activity, and four international and national awards later, our program is now known as one of the most experienced biotech incubators in the industry.
Early-stage bioscience companies face many challenges like the high cost of bringing products to market, regulatory hurdles and the need for specialized facilities and equipment. The Sid Martin Biotechnology Institute helps companies overcome these barriers and move scientific discoveries to the marketplace more quickly and affordably by providing laboratory space, introductions to investors, early recruitment of experienced leadership, networking opportunities, seminars and much more.
Creating a successful biotech company is never easy but we’ll be here for you – providing best practices in facilities, mentoring, advising and growth strategies for your company, each step of the way.
“Many of life’s failures are people who did not realize how close they were to success when they gave up.” ~Thomas Edison
Aavet Therapeutics, LLC is developing a safe and effective antigen-based immunotherapy program using a common immunization procedure for the prevention and treatment of cancer. Briefly, tumor-antigen genes carried by a patented bioengineered viral vector (AAV) are delivered to dendritic cells using a standard needle injection. Upon transduction, the dendritic cells express and display the tumor antigen and activate other components of the immune system, most notably T-cells. These activated immune cells specifically seek out and destroy tumor cells. Contact: Richard Wagner, CEO / 812.369.1127 / firstname.lastname@example.org
AlphaChem Innovations, Inc. is a start-up chemical company with a broad range of expertise in organic synthesis, natural products, and drug discovery. The company is developing several life science related innovations which will be translated into commercializable products. The first of these is a new chemical method for controlling Varroa mites in honey bees. AlphaChem provides contract research and manufacturing services for industrial clients. This includes custom synthesis of novel organic compounds, methods development, scale-up, and manufacturing. Contact: George Nikonov, President / email@example.com
AP LifeSciences is a biotechnology company that provides affordable one-step test kits for monitoring specific components in urine and blood. Our mission is to enable doctors and patients to take an active role in maintaining their health with easy-to-use one-step tests. Our first product, Oxalate testing kit, uses our patented technology to monitor oxalate levels in urine and blood, which are commonly high in patients with kidney stones. Because our tests can be easily done at home or at a physician’s office, they save the patients’ time and money, as current tests for monitoring oxalate levels need to be done in a laboratory. Contact: Cuong Quoc Nguyen, CEO / firstname.lastname@example.org
Assembly Biosciences, Inc. is a public biotechnology company advancing a new class of oral biologic therapeutics for leveraging the therapeutic potential of the gut microbiome and novel approaches to discovering and developing therapeutics for the treatment of hepatitis B virus (HBV) infection. Contact: Wayne Herber / email@example.com
Avekshan LLC is a pharmaceutical company developing efficacious and safe treatments for neuropsychiatric conditions affecting children and adults. Currently Avekshan is developing a non-stimulant, non-addictive drug for the treatment of attention deficit hyperactivity disorder (ADHD). Current generation of stimulant medications available for the treatment of ADHD suffer from serious drawbacks including potential for misuse, abuse and addiction. Although stimulants are highly effective, the drawbacks limit their acceptance and use. The rate of ADHD diagnosis is on the rise worldwide, highlighting an urgent need for safe and efficacious treatments. Avekshan is committed to fulfilling this critical global need. Contact: Pradeep G. Bhide, Ph.D., Founder and President / firstname.lastname@example.org
High value compounds of pharmacological importance are often extracted at very low levels from its native source. Here at BioGenX Inc., our mission is to metabolically engineer GRAS level microorganisms for the scalable production of valuable chemical compounds. This involves functional cloning and expression of recombinant biosynthetic pathways into these microorganisms that are commonly used in industry for the mass production of other compounds. Advantages of using these microorganisms for production over current extraction from native sources include fast growth rates, low cost in growth substrates, and ease of scalability. The successful expression of these recombinant pathways will provide the pharma industry with the neXt GENeration BIOsynthesis.
BioRegency, Inc. is pursuing two areas of study. One is a therapy for sepsis and the other is to validate potential biomarkers for sepsis. Sepsis is a complex disease caused by infections that lead to multi-organ failure and death in up to 50% of those affected particularly neonates and the elderly, despite advanced antibiotic treatment. Contact: Stephen Larner, Founder and CEO / 386.518.5775 / email@example.com
Captozyme founded in 2009, develops novel consumer food products and therapeutics using proprietary enzymes. The company is dedicated to the prevention and treatment of debilitating oxalate-related conditions. In 2016, Captozyme is introducing a food for special dietary use and a line of oxalate-free foods to address oxalate sensitivity. Oxalate is the main component in 80% of all kidney stones fanned. Their proprietary enzymes can also be developed as standalone therapeutics to address more severe oxalate-related disease. Contact: Aaron Cowley / firstname.lastname@example.org
Curtiss Healthcare is biopharmaceutical company developing a platform of new vaccines designed to help make our world a safer place through technologies that improve food quality and safety and help treat and prevent serious infections in humans and animals. Contact: Thomas Bigger, CEO / 781-856-1647 / email@example.com
GenomeGyde, LLC specializes in the development and commercialization of novel diagnostic biomarkers and tests. We offer Pharmacogenetic/Genetic testing and consulting for the public and private sectors. GenomeGyde works closely with clinicians to provide quick and cost-effective services and with researchers to further advance their genetic diagnostic technologies. Contact: Richard Wagner, CEO / 812.369.1127 / firstname.lastname@example.org
Lacerta Therapeutics is a startup gene therapy company dedicated to the development of innovative therapies for diseases of the Central Nervous System (CNS) that will provide long term efficacy to patients. The company will initially focus on rare diseases caused by single gene defects, where it believes its technology will have a major impact on patient’s lives. Its lead programs are focused on Pompe’s Disease (GAA deficiency), N-acetyl-glucosaminidase (NAGLU) deficiency (Sanfilippo Syndrome Type B) and spinal cerebellar ataxia (SCA). The company also has a development program for Alzheimer’s disease. Contact: Dr. Nicholas Muzyczka, CEO / email@example.com
Medosome Biotec, LLC The mission of Medosome Biotec, LLC (“MBT”) is to develop and commercialize technologies that enrich the lives of children by providing solutions to childhood diseases, disabilities and deficiencies. MBT works in collaboration with the Department of Pediatrics and Department of Medicine in the College of Medicine at the University of Florida to expedite the commercialization of the technology created in these departments. Contact: Richard Wagner, CEO / 812.369.1127 / firstname.lastname@example.org
MLM Biologics, Inc. Founded on the modern interpretation of the Gandhian Economic Principle of “More for Less for Many”, MLM Biologics is a Florida-based, start-up company focused on the advanced wound care and musculoskeletal markets. The company has developed a proprietary platform of biologic products for wound care, that are clinically- and cost-effective to serve the needs of patients worldwide. Operating out of the Sid Martin Biotechnology Institute, MLM Biologics, an ISO-13485 certified company is currently commercializing its first product, the bio-ConneKt Wound Matrix: an FDA-cleared medical device for clinically managing a variety of chronic, acute, and burn wounds. Contact: Chandra Nataraj, President / 352.514.4269 / email@example.com; Ken Harvey, Vice President / 352.278.3060 / firstname.lastname@example.org
OneVax LLC is a pre-clinical stage biotechnology company committed to developing novel and effective therapies for type 1 diabetes and other auto-immune diseases. OneVax has developed a propriety biomaterial vaccine delivery platform consisting of subcutaneously injectable PLGA microparticles (MPs) loaded with immunomodulatory agents capable of restoring immune tolerance and ultimately curing type 1 diabetes. Non-phagocytosable MPs or self-assembling hydrogel ensure sustained release of select agents designed to create a tolerogenic microenvironment while phagocytosable MPs allow for uptake and subsequent tolerogenic presentation of specific antigens by antigen presenting cells. OneVax’s therapy is minimally invasive, requires no cell isolation and storage and, due to its stable composition, has an extended shelf-life, simplifying manufacturing and shipping. Contact: Mark Atkinson, CEO / email@example.com
ReliOx Corporation. Microbial Contamination Control through Advanced ClO2 Solutions
RelīOxTM proprietary technology is a leap forward in Advanced Materials for Chemistry. The Patented core technology allows for safe production and transportation of high value added chemicals. RelīOx is about safety in chemical production, safety in the environment and is about sustainability. RelīOx is the future for global pathogen prevention and control. RelīOx offers revolutionary products and solutions for Odor Control in all global markets today! Contact: Ian Knapp, CEO / 786-942-5493 / firstname.lastname@example.org